Antibody tests that can detect whether people have been exposed to new variants of Covid-19 have been developed by scientists at Aberdeen University.

The new tests can detect antibody responses to infection by the SARS-CoV-2 virus with more than 98% accuracy, compared to the current rate of 60-93% and it is hoped they will soon be rolled out to the NHS.

For the first time, the new tests can be used to estimate the prevalence of circulating variant strains in the community including the variants first identified in Kent and in India, now known as the Alpha and Delta variants.

The tests can also assess the long-term immunity of an individual and whether immunity is vaccine-induced or is a result of previous exposure to the infection – information that is invaluable in helping to prevent the spread of infection.  

READ MORE: Nicola Sturgeon to give lockdown update today amid fears Delta variant could delay restriction easing 

In addition to this, they can also provide information that can be used to estimate the duration of the immunity provided by the vaccine as well  as the effectiveness of the vaccine on emerging variants.

This is an improvement on the currently available tests that struggle to detect variants and give little or no information on the impact of virus mutations on vaccine performance.  

Professor Mirela Delibegovic from the University of Aberdeen and academic lead on the project said: “Accurate antibody tests will become increasingly important in the management of the pandemic and this is a truly game-changing technology with the potential to dramatically change the trajectory of global recovery from the pandemic.” 

Professor Delibegovic worked alongside industry partners, Vertebrate Antibodies and colleagues in NHS Grampian to develop the new tests using technology known as Epitogen. 

The team used artificial intelligence called EpitopePredikt to identify specific elements, or ‘hot spots’ of the virus that trigger the body’s immune defence.

READ MORE: Scots urged to check for cancer signs amid concern over 'missing' cases 

The researchers were then able to develop a new way to display these viral elements as they would appear naturally in the virus, using a biological platform they named EpitoGen Technology. 

As well as Covid-19, the EpitoGen platform can be used for the development of highly sensitive and specific diagnostic tests for infectious and auto-immune diseases such as Type 1 Diabetes. 

Professor Delibegovic added: “As we move through the pandemic we are seeing the virus mutate into more transmissible variants such as the Delta variant whereby they impact negatively on vaccine performance and overall immunity. Currently available tests cannot detect these variants. 

READ MORE: Vaccines 'highly effective' at preventing hospital admissions in Delta variant cases 

"As the virus mutates, existing antibody tests will become even less accurate hence the urgent need for a novel approach to incorporate mutant strains into the test – this is exactly what we have achieved. 

“Looking ahead, discussions are already underway to explore a possible roll-out of the tests to the NHS which we hope to see happen soon.” 

Dr Brittain-Long, Consultant in Infectious Diseases in NHS Grampian and a member of the research team adds: “This new testing platform adds crucial sensitivity and specificity to the current available serology tests and has the potential to monitor individual and population based immunity in a way that has not been possible before."